Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes.
Diabetes Obes Metab · 2014
Last updated 2026-05-28In a study of 16 Japanese patients with type 2 diabetes, liraglutide slowed stomach emptying in 7 patients (delayers) by an average of 31 minutes, while it had little to no effect in the other 9 patients (non-delayers). The delayers also showed a larger early drop in blood sugar levels without a corresponding increase in insulin. The results suggest liraglutide’s impact on stomach emptying varies among individuals.
AI summary of the abstract below.
| Journal | Diabetes Obes Metab, 2014 |
|---|---|
| Citations | 13 |
| Relative citation ratio | 0.48 |
| NIH percentile | 28 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
This study was performed to clarify the influence of liraglutide on gastric emptying in Japanese patients with type 2 diabetes. In 16 patients, the [(13) C]-acetate breath test was performed to compare gastric emptying before and after liraglutide treatment. We found two patterns of response, with gastric emptying being delayed by liraglutide in seven patients (delayers) and not delayed in nine patients (non-delayers). The mean increase of the maximum gastric emptying time was 31 ± 4 min (p < 0.01 vs. baseline) in the delayers, while it was only 2 ± 3 min (p = 0.60 vs. baseline) in the non-delayers. The delayers showed a greater early decrease of AUC-PG from 0 to 60 min, despite no increase of the plasma insulin level compared with non-delayers. In conclusion, the effect of liraglutide treatment on gastric emptying shows heterogeneity, and patients can be classified as delayers or non-delayers.
Verbatim abstract via PubMed 24320758 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.